Document is current
Any future updates will be listed below
-
Authors
Nishii, Shota
Akatani, Ritsu
Shiroma, Kyoka
Takeda, Ryosuke
Tsuji, Asato
Katanazaka, Kimitaka
Matoba, Kento
Otani, Mayumi
Koto, Shusuke
Tanaka, Kazuhiro
Nagashima, Hiroaki
Sekiguchi, Kenji
Sasayama, Takashi
Chihara, Norio https://orcid.org/0000-0003-4499-0790
-
Funding
Funding for this research was provided by:
AMED Practical Research Project for Rare / Intractable Diseases (JP25ek0109824)
Japan Agency for Medical Research and Development (JP256f0137011)
Ministry of Education, Culture, Sports, Science and Technology > Japan Society for the Promotion of Science (23K27488)
Kobe University
- License Information
-
More Information
Article History
Received: 30 January 2026
Revised: 15 March 2026
Accepted: 17 March 2026
First Online: 2 April 2026
Declarations
:
: NC has received honoraria for lectures from Biogen Japan, Novartis, Tanabe Pharma, Chugai Pharmaceutical, and Alexion Pharmaceuticals. The other authors declare no competing interests.
: Not applicable.
: The protocol was approved by Kobe University Clinical Research Ethical Committee (B250069) in accordance with the Declaration of Helsinki. Because the research involved the use of existing clinical data, informed consent was obtained through an opt-out process. Study information was publicly available on the institutional website, providing patients with the opportunity to withdraw their data from the analysis.
